PL375532A1 - Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów - Google Patents

Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów

Info

Publication number
PL375532A1
PL375532A1 PL03375532A PL37553203A PL375532A1 PL 375532 A1 PL375532 A1 PL 375532A1 PL 03375532 A PL03375532 A PL 03375532A PL 37553203 A PL37553203 A PL 37553203A PL 375532 A1 PL375532 A1 PL 375532A1
Authority
PL
Poland
Prior art keywords
benzimidazol
cancer
treatment
thiophene compounds
thiophene
Prior art date
Application number
PL03375532A
Other languages
English (en)
Inventor
Clarence W.Iii Andrews
Mui Cheung
Ronda G. Davis-Ward
David Harold Drewry
Kyle Allen Emmitte
Robert Dale Hubbard
Kevin W. Kuntz
James Andrew Linn
Robert Anthony Mook Jr.
Gary Keith Smith
James Marvin Veal
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of PL375532A1 publication Critical patent/PL375532A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03375532A 2002-08-08 2003-08-04 Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów PL375532A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40200802P 2002-08-08 2002-08-08

Publications (1)

Publication Number Publication Date
PL375532A1 true PL375532A1 (pl) 2005-11-28

Family

ID=31715769

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375532A PL375532A1 (pl) 2002-08-08 2003-08-04 Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów

Country Status (18)

Country Link
US (2) US20060074119A1 (pl)
EP (1) EP1546137A1 (pl)
JP (1) JP2006505522A (pl)
KR (1) KR20050071471A (pl)
CN (1) CN1688576A (pl)
AU (1) AU2003265348B2 (pl)
BR (1) BR0313160A (pl)
CA (1) CA2493908A1 (pl)
IL (1) IL166328A0 (pl)
IS (1) IS7657A (pl)
MA (1) MA27427A1 (pl)
MX (1) MXPA05001544A (pl)
NO (1) NO20050525L (pl)
NZ (1) NZ538134A (pl)
PL (1) PL375532A1 (pl)
RU (1) RU2296758C2 (pl)
WO (1) WO2004014899A1 (pl)
ZA (1) ZA200500864B (pl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
RU2006108803A (ru) * 2003-08-21 2007-09-27 Оси Фармасьютикалз, Инк. (Us) N-замещенные бензимидазолильные ингибиторы с-kit
JP2007509070A (ja) * 2003-10-16 2007-04-12 スミスクライン ビーチャム コーポレーション チオフェン化合物
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
ES2305887T3 (es) 2003-12-18 2008-11-01 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos.
WO2005075470A1 (en) 2004-01-28 2005-08-18 Smithkline Beecham Corporation Thiazole compounds
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006025567A1 (ja) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. 新規置換イミダゾール誘導体
WO2006049339A1 (ja) * 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. 新規縮環イミダゾール誘導体
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
CA2590939C (en) 2004-12-17 2011-10-18 Amgen Inc. Aminopyrimidine compounds and methods of use
BRPI0615705A2 (pt) * 2005-09-06 2016-08-23 Smithkline Beecham Corp processo para preparar um composto, e, composto
KR20080047585A (ko) * 2005-09-06 2008-05-29 스미스클라인 비참 코포레이션 벤즈이미다졸 티오펜 화합물
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
DE602006012694D1 (de) * 2005-09-06 2010-04-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk-modulatoren
JP5498703B2 (ja) * 2006-01-23 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US7504513B2 (en) * 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
CN101466708A (zh) 2006-04-13 2009-06-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的噻吩甲酰胺
CN101495474A (zh) * 2006-05-23 2009-07-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
EP2027116A2 (en) * 2006-05-23 2009-02-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009539771A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション 置換ベンゾイミダゾールチオフェンベンジルエーテル化合物
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
US8492377B2 (en) 2006-07-13 2013-07-23 Janssen Pharmaceutica Nv MTKI quinazoline derivatives
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
WO2008070354A2 (en) * 2006-10-31 2008-06-12 Smithkline Beecham Corporation 5- and 6- substituted benzimidazole thiophene compounds
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
WO2009002916A2 (en) * 2007-06-26 2008-12-31 Smithkline Beecham Corporation Processes for preparing benzimidazole thiophenes
US8273890B2 (en) * 2007-06-29 2012-09-25 4Sc Ag Thiophene-imidazopyridines
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
RU2501787C2 (ru) * 2007-11-02 2013-12-20 Метилджен Инк. Ингибиторы гистондеацетилазы
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
CA2745596A1 (en) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
EP2391619A1 (en) 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8609711B2 (en) * 2009-01-30 2013-12-17 Glaxosmithkline Llc Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
NZ607087A (en) 2010-08-11 2015-05-29 Millennium Pharm Inc Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CA2860323C (en) * 2011-12-28 2022-03-08 The Regents Of The University Of California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
HUE040025T2 (hu) 2012-08-24 2019-02-28 Univ Texas A HIF aktivitás heterociklusos modulátorai betegség kezelésére
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20160083343A1 (en) * 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP2018531213A (ja) 2015-03-13 2018-10-25 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
MD3880654T2 (ro) 2018-11-19 2022-05-31 Global Blood Therapeutics Inc Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859648A (en) * 1984-12-28 1989-08-22 Mobil Oil Corporation Layered metal chalcogenides containing interspathic polymeric chalcogenides
FR2600000B1 (fr) * 1986-06-13 1989-04-14 Extramet Sa Procede et dispositif de granulation d'un metal fondu
US4818270A (en) * 1986-08-28 1989-04-04 Monsanto Company 2-(Heteroamino)-4,5-substituted-oxazole/thiazole compounds as herbicide antidotes, compositions and use
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US5151424A (en) * 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US5342957A (en) * 1988-11-29 1994-08-30 Janssen Pharmaceutica N.V. Benzimidazoles useful in treating epithelial disorders
US5627199A (en) * 1991-03-28 1997-05-06 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz [CD] indoles
US5457102A (en) * 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
AU7715198A (en) * 1997-06-04 1998-12-21 Eli Lilly And Company Anti-viral compounds
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
WO2000012089A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6358738B1 (en) * 1998-05-13 2002-03-19 The President And Fellows Of Harvard College Polo box therapeutic compositions, methods, and uses therefor
TR200100084T2 (tr) * 1998-07-16 2001-07-23 Aventis Pharma Deutschland Gmbh İlaç olarak fosfin-ve fosfon asit türevleri
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
US6642425B2 (en) * 2002-03-05 2003-11-04 Sasol North America Inc. Reactive distillation process for the alkylation of aromatic hydrocarbons
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists

Also Published As

Publication number Publication date
ZA200500864B (en) 2006-04-26
US20080269298A1 (en) 2008-10-30
MXPA05001544A (es) 2005-04-19
NO20050525L (no) 2005-05-06
EP1546137A1 (en) 2005-06-29
NZ538134A (en) 2006-03-31
RU2005102390A (ru) 2006-01-10
US20060074119A1 (en) 2006-04-06
AU2003265348B2 (en) 2007-08-16
BR0313160A (pt) 2005-07-12
JP2006505522A (ja) 2006-02-16
IS7657A (is) 2005-01-20
CN1688576A (zh) 2005-10-26
MA27427A1 (fr) 2005-07-01
WO2004014899A1 (en) 2004-02-19
CA2493908A1 (en) 2004-02-19
AU2003265348A1 (en) 2004-02-25
IL166328A0 (en) 2006-01-15
RU2296758C2 (ru) 2007-04-10
KR20050071471A (ko) 2005-07-07

Similar Documents

Publication Publication Date Title
PL375532A1 (pl) Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów
EP1613308A4 (en) CANCER TREATMENT METHODS
IL164599A0 (en) Combination therapy for the treatment of cancer
PL372211A1 (pl) Tiazolilomoczniki w leczeniu raka
HK1097410A1 (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
EP1599196A4 (en) ANTICANCER THERAPY
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003212634A8 (en) Compounds useful in the treatment of cancer
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
IL175689A0 (en) Enoxaparin for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
AU2003231803A8 (en) Treatment of cancer with mefloquire
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
GB0329416D0 (en) Treatment of cancer
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB2415379B (en) Methyl-ß-orcinolcarboxylate from lichen (everniasrum cirrhatum) for use for the treatment of cancer
GB2383538B (en) Cancer treatment
GB0324482D0 (en) Methods for the treatment of cancer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)